iBio
Cory Schwartz has a diverse work experience spanning multiple roles and companies. They started their career as an Undergraduate Researcher at The Ohio State University from 2010 to 2012. They then worked as a Graduate Research Assistant at the University of Nebraska–Lincoln from 2012 to 2014. Following this, Cory joined the University of California, Riverside as a PHD Candidate from 2014 to 2018.
In 2019, Cory transitioned into industry and joined Pfenex Inc. They served as an Associate Scientist II in Strain Engineering from January to September 2019. They then took on the role of Scientist in Drug Discovery from September 2019 to October 2020, before being promoted to Senior Scientist in Drug Discovery from October 2020 to July 2021.
Currently, Cory is working at iBio, Inc. as a Senior Scientist since July 2021. They have recently been promoted to the position of Principal Scientist, starting in September 2022.
Cory Schwartz completed their education with a Bachelor of Science (B.S.) degree in Microbiology from The Ohio State University from 2007 to 2012. Cory then pursued a Master of Science (M.S.) degree in Chemical and Biomolecular Engineering from the University of Nebraska-Lincoln from 2012 to 2014. Finally, they earned a Doctor of Philosophy (PhD) degree in Chemical Engineering from the University of California, Riverside, where they studied from 2014 to 2018.
This person is not in any offices
iBio
iBio is an innovator biologics company developing therapeutics and vaccines for the betterment of human and animal health, including a virus-like particle (VLP) -based vaccine against SARS-CoV-2. iBio’s subsidiary, iBio CDMO is a global leader in plant-based manufacturing. It’s FastPharming™ and FastGlycaneering™ platforms provide contract development and manufacturing services via its 130,000 square foot facility in Bryan, Texas. The speed and scalability of FastPharming make it an ideal choice for other innovator companies who want to rapidly produce COVID-19 biologics.